http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI1102276-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b2d7de97d928f717df356c027a9f833 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-08 |
| filingDate | 2011-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98efa1f936aa5c1757b3e5d65090fd2d |
| publicationDate | 2015-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI1102276-A2 |
| titleOfInvention | Organic composition indicated for the treatment of epidermal infectious, inflammatory and antineoplastic processes in mammals |
| abstract | Organic composition indicated for the treatment of infectious, inflammatory and epidermal antineoplastic processes in mammals. This invention was conceived with the purpose of promoting the treatment of all types of epidermal infectious, inflammatory and neoplastic processes that affect mammals through the use of a composition composed of organic active ingredients present in propolis and ginger alcoholic dyes and oily extracts of sunflower and copaiba, all in a concentration of 5 to 20% contained in hypertonic solution of mannitol or optionally other sugars such as xylitol, sorbitol, fructose or glucose in the concentration of 20% plus the polysorbate that has the function of emulsifier making the solution. homogeneous. The injection or topical use of the composition is performed directly on the neoplastic tissue or on the area affected by the infectious or inflammatory process. The therapeutic principle is based on the action of mannitol on the cellular environment. Due to the hyperosmolarity conferred to the medium by its action, there is an increase in the permeability of the cell membranes, both normal and those affected by the mentioned diseases, thus allowing the active principles contained in the formula to penetrate them exerting their action. therapy. Once present within the cellular cytoplasm, the active ingredients promote the antineoplastic, antiinflammatory, and antibiotic effects that consist among others of antimetabolic and antiangiogenic action. The application of the composition does not cause pain and, unlike conventional antineoplastic treatments such as chemotherapy and radiotherapy, is free of side effects, since, unlike the compositions containing in its formulation antibiotics and anti-inflammatories, it does not induce resistance by the body to active ingredients or the loss of immunity |
| priorityDate | 2011-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.